Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Producer : inconnu
  • Active substance : escitalopram
  • Active substance : olanzapine
  • Active substance : rivastigmine
  • Active substance : sodium
  • Topics : Population groups
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Rehabilitation techniques (1)
    • Drug therapy (1)
    • Psychotherapies (1)
  • Diseases and conditions (1)
  • Plus ...
    • Mental disorders and behavioural conditions (1)
    • Plus ...
      • Disorders of psychological development (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Manufacturer
  • inconnu (1)
  • industriels (1)
Language
  • Français (1)
Active substance
  • alanine (1)
  • alcool (1)
  • aripiprazole (1)
  • chlorpromazine (1)
  • citalopram (1)
  • escitalopram (1)
  • famotidine (1)
  • mirtazapine (1)
  • olanzapine (1)
  • pentoxifylline (1)
  • pimozide (1)
  • pyridoxine (1)
  • rivastigmine (1)
  • sodium (1)
  • topiramate (1)
 More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 1 result

  • Autism and other PDDs: coordinated education and treatment interventions in children and adolescents

    Practice guidelines - Posted on 8/3/2012
    Download abstract
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
1fL3p4486jYTq5wv